Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137

Site search

Correspondence address
310 Mira Street, Stavropol, Russia, 355017

+7 8652 352524; +7 8652 353229.

+7 8652 352524.


Role of galectin -3 in diagnostics and treatment control in patients with heart failure

[Clinical Pharmacology] [Pharmacology]
Vladimir Kukes; Karine Gyamdzhyan; Anna Zhestovskaia; Yury Olefir; Valeriy Marinin; Alexey Prokofiev;

The aim of the study was to assess clinical value of galectin-3 levels evaluation in patients with heart failure. The study results demonstrated decrease of plasma galectin-3 levels after pharmacotherapy. The decrease of galectin-3 levels was accompanied by clinical improvement in patients with heart failure. Thus, galectin-3 can be used as an additional biomarker for HF diagnostics and pharmacotherapy monitoring in patients with heart failure.


1. Kim H., Lee J., Hyun J. W., Park J. W., Joo H., Shin T. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell. Biol. Int. 2007;31(7):655-662.
2. Tang W. H. W., Shrestha K., Shao Z., Borowski A. G. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am. J. Cardiol. 2011;108(3):385-390. https://doi.org/10.1016/j.amjcard.2011.03.056
3. Ueland T., Aukrust P., Broch K., Aakhus S. Galectin-3 in heart failure: High levels are associated with allcause mortality. Int. J. Cardiol. 2011;150(3):361-364. https://doi.org/10.1016/j.ijcard.2011.05.081
4. Mareev V. Yu., Fomin I. V., Ageev F. T., Arutyunov G. P., Begrambekova Yu. L., Belenkov Yu. N. Klinicheskie rekomendacii. Khronicheskaya serdechnaya nedostatochnost. Serdechnaya nedostatochnost. – Heart Failure Journal. (XSN). 2017;18(1):3-40. (In Russ). https://doi.org/10.18087/rhfj.2017.1.2346
5. Anand I. S., Rector T. S., Kuskowski M., Adourian A., Muntendam P., Cohn J. N. Baseline and serial measurements of galectin-3 in patients with heart failure: Relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur. J. Heart Fail. 2013;15(5):511-518. https://doi.org/10.1093/eurjhf/hfs205
6. Motiwala S. R., Szymonifka J., Belcher A., Weiner R. B. Serial measurement of galectin-3 in patients with chronic heart failure: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur. J. Heart Fail. 2013;15(10):1157-1163. https://doi.org/10.1093/eurjhf/hft075
7. van Kimmenade R. R., Januzzi J. L., Ellinor P. T., Sharma U. C. Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure. J. Am. Coll. Cardiol. 2006;48(6):1217-1224. https://doi.org/10.1016/j.jacc.2006.03.061
8. Januzzi J. L., Camargo C. A., Anwaruddin S., Baggish A. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am. J. Cardiol. 2005;95(8):948-954. https://doi.org/10.1016/j.amjcard.2004.12.032
9. Deveci O. S., İelik A. İ., İkikardeş M. F., Cagliyan C. E. A Novel BioTarget in Treatment of Heart Failure: Changes in Serum Galectin-3 Levels after Spironolactone Therapy. J. Hypertens. Open. Access. 2015;04(01):1-4. https://doi.org/10.4172/2167-1095.1000195
10. Richards A. M., Doughty R., Nicholls M. G., MacMahon S. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J. Am. Coll. Cardiol. 2001;37(7):1781-1787. https://doi.org/10.1016/S0735-1097(01)01269-4

Keywords: galectin-3, NT-proBNP, biomarkers, chronic heart failure

Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy